The 48% overall response rate (ORR) in 42 heavily pre-treated AML patients marks a notable benchmark. Median prior therapies: 3. All patients had failed at least one venetoclax-based regimen. The 30% composite complete remission rate (CRc) in FLT3-mutated patients, all of whom had progressed on gilteritinib, suggests a potential salvage path in a notoriously resistant subset.
Cytokine release syndrome (CRS) occurred in 55% of patients, but only 7% were Grade ≥3. No treatment-related deaths. The safety profile is cleaner than blinatumomab’s historical data, where Grade ≥3 CRS hits ~15%. This may allow outpatient dosing, a key competitive edge over Amgen’s BiTE platform.
The data set ELE-101 apart from other CD33-targeting bispecifics. Compared to Xencor’s XmAb14045 (CD123xCD3), which posted a 26% ORR in a similar setting, ELE-101’s 48% ORR doubles the response rate. However, the small sample size (n=42) and single-arm design warrant caution. A randomized Phase 3 vs. standard of care is planned for 2025.
“ELE-101’s 48% ORR in a population with a median of 3 prior therapies is a clear signal. The FLT3-mutated data are particularly striking given gilteritinib resistance.” — Lead investigator, Dr. Marina Konopleva
Looking ahead, the key question is durability. Median duration of response was not reached at a median follow-up of 8.2 months, but early censoring limits interpretation. If the 6-month landmark analysis shows >50% of responders in remission, ELE-101 could become a new standard for post-venetoclax failure. Elevation’s stock surged 22% on the data, reflecting investor optimism, but the path to registration requires a confirmatory trial.
